Paradigm Biopharmaceuticals (ASX:PAR) has announced that it has received firm commitments for a capital raising totalling $16 million through a placement of fully paid ordinary shares to sophisticated and institutional investors. …
Paradigm completes $16 million capital raise to support global Phase 3 clinical trial
December 9, 2024 Australian Biotech
Latest Video
New Stories
-
NDIS keeps growing but signs emerge that reforms are starting to work
July 17, 2025 - - Latest News -
USTR launches new investigation, with minimal ambition on pharmaceuticals
July 17, 2025 - - Latest News -
New Zealand starting to benefit after lifting advertising prohibition
July 17, 2025 - - Latest News -
Mark Butler restates support for health technology assessment reform
July 16, 2025 - - Latest News -
Brandon BioCatalyst welcomes the inclusion of its CUREator in new program
July 16, 2025 - - Australian Biotech -
Cancer Australia launches research program targeting early-onset cancers
July 16, 2025 - - Latest News -
Imugene completes significant placement and launches share purchase plan
July 16, 2025 - - Australian Biotech